miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
暂无分享,去创建一个
R. Komers | P. Kantharidis | C. Winbanks | P. Gregorevic | J. Jha | M. Herman-Edelstein | Shinji Hagiwara | A. McClelland | M. Cooper
[1] T. Tuschl,et al. MicroRNA-21 in glomerular injury. , 2015, Journal of the American Society of Nephrology : JASN.
[2] Naoki Nakagawa,et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. , 2015, The Journal of clinical investigation.
[3] A. Tobar,et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy , 2014, Journal of Lipid Research.
[4] J. Mi,et al. MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation , 2013, Scientific Reports.
[5] Xianzhong Xiao,et al. MicroRNA-21 in Scleroderma Fibrosis and its Function in TGF-β- Regulated Fibrosis-Related Genes Expression , 2013, Journal of Clinical Immunology.
[6] N. Pottier,et al. Increased Circulating miR-21 Levels Are Associated with Kidney Fibrosis , 2013, PloS one.
[7] H. Lan,et al. Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] R. Müller,et al. Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT) , 2013, Journal of Molecular Medicine.
[9] Xiao-ming Meng,et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes , 2013, Diabetologia.
[10] B. Kasinath,et al. TGFβ-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion , 2012, PloS one.
[11] L. Hunyady,et al. Crosstalk between TGF-β signaling and the microRNA machinery. , 2012, Trends in pharmacological sciences.
[12] V. Patel,et al. MicroRNAs and fibrosis , 2012, Current opinion in nephrology and hypertension.
[13] P. Pandolfi,et al. The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.
[14] C. Feschotte,et al. Endogenous viruses: insights into viral evolution and impact on host biology , 2012, Nature Reviews Genetics.
[15] Aaron N. Chang,et al. MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways , 2012, Science Translational Medicine.
[16] Merlin C. Thomas,et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. , 2012, Journal of the American Society of Nephrology : JASN.
[17] A. Ghosh,et al. PAI‐1 in tissue fibrosis , 2012, Journal of cellular physiology.
[18] Xiao-ming Meng,et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. , 2011, Journal of the American Society of Nephrology : JASN.
[19] Bo Wang,et al. Diabetes Complications: The MicroRNA Perspective , 2011, Diabetes.
[20] Falguni Das,et al. MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes* , 2011, The Journal of Biological Chemistry.
[21] M. Cooper,et al. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy. , 2011, Kidney international.
[22] Merlin C. Thomas,et al. miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression , 2010, Diabetes.
[23] J. Iacomini,et al. Identification of a microRNA signature of renal ischemia reperfusion injury , 2010, Proceedings of the National Academy of Sciences.
[24] W. Filipowicz,et al. Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.
[25] M. Lindsay,et al. MicroRNAs and the regulation of fibrosis , 2010, The FEBS journal.
[26] N. Kaminski,et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.
[27] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[28] B. Harfe,et al. The microRNA-processing enzyme dicer maintains juxtaglomerular cells. , 2010, Journal of the American Society of Nephrology : JASN.
[29] F. Brosius,et al. Abnormalities in signaling pathways in diabetic nephropathy , 2010, Expert review of endocrinology & metabolism.
[30] Ziying Liu,et al. Regulation of TGF-β signaling by Smad7 , 2009, Acta biochimica et biophysica Sinica.
[31] J. Rossi,et al. TGF-β activates Akt kinase via a microRNA-dependent amplifying circuit targeting PTEN , 2009, Nature Cell Biology.
[32] E. Olson,et al. Searching for miR-acles in cardiac fibrosis. , 2009, Circulation research.
[33] Merlin C. Thomas,et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.
[34] G. Wolf,et al. Cellular and Molecular Mechanisms of Proteinuria in Diabetic Nephropathy , 2007, Nephron Physiology.
[35] S. Mader,et al. Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney , 2006, Diabetes.
[36] L. Gesualdo,et al. Pathogenetic mechanisms of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[37] Ying E. Zhang,et al. Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.
[38] R. Atkins,et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.
[39] Denis Vivien,et al. Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.
[40] Š. Čikoš,et al. Transformation of real-time PCR fluorescence data to target gene quantity. , 2009, Analytical biochemistry.